Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Common Stock	Preferred Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2019			$ 155,062	$ (264)	$ (144,266)	$ 10,532
Balance (in Shares) at Dec. 31, 2019	4,825,549	5,559		3
Issuance of common stock, common warrants and prefunded warrants (net of offering costs of $958)	$ 1		6,541			6,542
Issuance of common stock, common warrants and prefunded warrants (net of offering costs of $958) (in Shares)	3,245,745
Issuance of common stock (net of offering costs of $655)			5,095			5,095
Issuance of common stock (net of offering costs of $655) (in Shares)	2,090,909
Common warrant and prefunded warrant exercise	$ 1		7,138			7,139
Common warrant and prefunded warrant exercise (in Shares)	10,695,706
Net loss					(8,333)	(8,333)
Balance at Mar. 31, 2020	$ 2		173,836	$ (264)	(152,599)	20,975
Balance (in Shares) at Mar. 31, 2020	20,857,909	5,559		3
Balance at Dec. 31, 2020	$ 3		186,482	$ (264)	(156,603)	29,618
Balance (in Shares) at Dec. 31, 2020	34,920,219	5,559		3
Issuance of common stock and warrants (net of offering costs of $8,260)	$ 6		77,983			77,989
Issuance of common stock and warrants (net of offering costs of $8,260) (in Shares)	53,905,927
Exercise of warrants			84			84
Exercise of warrants (in Shares)	80,000
Issuance of common stock for research and development license acquired			531			531
Issuance of common stock for research and development license acquired (in Shares)	625,000
Stock-based compensation			112			112
Stock-based compensation (in Shares)
Net loss					(3,962)	(3,962)
Balance at Mar. 31, 2021	$ 9		$ 265,192	$ (264)	$ (160,565)	$ 104,372
Balance (in Shares) at Mar. 31, 2021	89,531,146	5,559		3